Literature DB >> 19240943

Lessons learned from the contamination of heparin.

Haiying Liu1, Zhenqing Zhang, Robert J Linhardt.   

Abstract

Heparin is unique as one of the oldest drugs currently still in widespread clinical use as an anticoagulant, a natural product, one of the first biopolymeric drugs, and one of the few carbohydrate drugs. Recently, certain batches of heparin have been associated with anaphylactoid-type reactions, some leading to hypotension and death. These reactions were traced to contamination with a semi-synthetic oversulfated chondroitin sulfate (OSCS). This Highlight reviews the heparin contamination crisis, its resolution, and the lessons learned. Pharmaceutical scientists now must consider dozens of natural and synthetic heparinoids as potential heparin contaminants. Effective assays, which can detect both known and unknown contaminants, are required to monitor the quality of heparin. Safer and better-regulated processes are needed for heparin production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19240943      PMCID: PMC3498470          DOI: 10.1039/b819896a

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   13.423


  48 in total

Review 1.  Structure and biological activity of mammalian glycosaminoglycans.

Authors:  B Casu
Journal:  Mod Probl Pharmacopsychiatry       Date:  1989

Review 2.  Fondaparinux: pharmacology and clinical experience in cardiovascular medicine.

Authors:  V Toschi; M Lettino
Journal:  Mini Rev Med Chem       Date:  2007-04       Impact factor: 3.862

3.  The FDA and safety--beyond the heparin crisis.

Authors:  Cato T Laurencin; Lakshmi Nair
Journal:  Nat Biotechnol       Date:  2008-06       Impact factor: 54.908

4.  A proteoglycan form of heparin and its degradation to single-chain molecules.

Authors:  H C Robinson; A A Horner; M Höök; S Ogren; U Lindahl
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

Review 5.  Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.

Authors:  Rodger L Bick; Eugene P Frenkel; Jeanine Walenga; Jawed Fareed; Deborah A Hoppensteadt
Journal:  Hematol Oncol Clin North Am       Date:  2005-02       Impact factor: 3.722

6.  Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin.

Authors:  J Sudhalter; J Folkman; C M Svahn; K Bergendal; P A D'Amore
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

7.  Chlorbutol, a new inhibitor of aldosterone biosynthesis identified during examination of heparin effect on aldosterone production.

Authors:  S J Sequeira; T J McKenna
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

8.  Contribution of monosaccharide residues in heparin binding to antithrombin III.

Authors:  D H Atha; J C Lormeau; M Petitou; R D Rosenberg; J Choay
Journal:  Biochemistry       Date:  1985-11-05       Impact factor: 3.162

Review 9.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

10.  Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures.

Authors:  Jinghua Chen; Courtney L Jones; Jian Liu
Journal:  Chem Biol       Date:  2007-09
View more
  119 in total

1.  Development of delivery methods for carbohydrate-based drugs: controlled release of biologically-active short chain fatty acid-hexosamine analogs.

Authors:  Udayanath Aich; M Adam Meledeo; Srinivasa-Gopalan Sampathkumar; Jie Fu; Mark B Jones; Christopher A Weier; Sung Yun Chung; Benjamin C Tang; Ming Yang; Justin Hanes; Kevin J Yarema
Journal:  Glycoconj J       Date:  2010-05-11       Impact factor: 2.916

2.  High cell density cultivation of a recombinant Escherichia coli strain expressing a 6-O-sulfotransferase for the production of bioengineered heparin.

Authors:  J Zhang; M Suflita; C M Fiaschetti; G Li; L Li; F Zhang; J S Dordick; R J Linhardt
Journal:  J Appl Microbiol       Date:  2014-12-02       Impact factor: 3.772

3.  Escherichia coli K5 heparosan fermentation and improvement by genetic engineering.

Authors:  Zhenyu Wang; Jonathan S Dordick; Robert J Linhardt
Journal:  Bioeng Bugs       Date:  2011 Jan-Feb

Review 4.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

5.  Chemoenzymatic design of heparan sulfate oligosaccharides.

Authors:  Renpeng Liu; Yongmei Xu; Miao Chen; Michel Weïwer; Xianxuan Zhou; Arlene S Bridges; Paul L DeAngelis; Qisheng Zhang; Robert J Linhardt; Jian Liu
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

6.  Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.

Authors:  Yongmei Xu; Elizabeth H Pempe; Jian Liu
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

7.  Cyclic AMP (cAMP) Receptor Protein-cAMP Complex Regulates Heparosan Production in Escherichia coli Strain Nissle 1917.

Authors:  Huihui Yan; Feifei Bao; Liping Zhao; Yanying Yu; Jiaqin Tang; Xianxuan Zhou
Journal:  Appl Environ Microbiol       Date:  2015-08-28       Impact factor: 4.792

8.  Structural Characterization of Glycosaminoglycan Carbohydrates Using Ultraviolet Photodissociation.

Authors:  Dustin R Klein; Franklin E Leach; I Jonathan Amster; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2019-04-11       Impact factor: 6.986

9.  Chemoenzymatic synthesis and structural characterization of 2-O-sulfated glucuronic acid-containing heparan sulfate hexasaccharides.

Authors:  Po-Hung Hsieh; Yongmei Xu; David A Keire; Jian Liu
Journal:  Glycobiology       Date:  2014-04-25       Impact factor: 4.313

10.  Molecular Mass Characterization of Glycosaminoglycans with Different Degrees of Sulfation in Bioengineered Heparin Process by Size Exclusion Chromatography.

Authors:  Zhenyu Wang; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Curr Anal Chem       Date:  2012-10-01       Impact factor: 1.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.